Assetmark, Inc Incyte Corp Transaction History

Assetmark, Inc

$34.9 Billion
Q3 2024

A detailed history of Assetmark, Inc transactions in Incyte Corp stock. As of the latest transaction made, Assetmark, Inc holds 108 shares of INCY stock, worth $7,550. This represents 0.0% of its overall portfolio holdings.

Number of Shares

108

Previous 251 56.97%

Holding current value

$7,550

Previous $15,000 53.33%

% of portfolio

0.0%

Previous 0.0%

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 01, 2024	SELL	$57.33 - $68.61 $8,198 - $9,811	-143 Reduced 56.97%	108 $7,000
Q2 2024 Aug 13, 2024	SELL	$51.18 - $63.75 $3.04 Million - $3.79 Million	-59,470 Reduced 99.58%	251 $15,000
Q1 2024 May 06, 2024	BUY	$56.55 - $66.59 $381,486 - $449,216	6,746 Added 12.73%	59,721 $3.4 Million
Q4 2023 Feb 09, 2024	BUY	$52.16 - $64.19 $264,294 - $325,250	5,067 Added 10.58%	52,975 $3.33 Million
Q3 2023 Oct 27, 2023	BUY	$57.77 - $65.93 $358,867 - $409,557	6,212 Added 14.9%	47,908 $2.77 Million
Q2 2023 Aug 11, 2023	BUY	$60.95 - $75.51 $1.2 Million - $1.49 Million	19,746 Added 89.96%	41,696 $2.6 Million
Q1 2023 May 05, 2023	BUY	$70.23 - $86.01 $138,142 - $169,181	1,967 Added 9.84%	21,950 $1.59 Million
Q4 2022 Feb 10, 2023	SELL	$67.18 - $84.11 $158,276 - $198,163	-2,356 Reduced 10.55%	19,983 $1.61 Million
Q3 2022 Nov 01, 2022	BUY	$66.18 - $82.86 $335,929 - $420,597	5,076 Added 29.4%	22,339 $1.49 Million
Q2 2022 Aug 03, 2022	BUY	$66.18 - $83.18 $140,367 - $176,424	2,121 Added 14.01%	17,263 $1.31 Million
Q1 2022 May 13, 2022	BUY	$66.02 - $79.71 $374,663 - $452,354	5,675 Added 59.95%	15,142 $1.2 Million
Q4 2021 Feb 14, 2022	BUY	$63.34 - $74.11 $426,974 - $499,575	6,741 Added 247.29%	9,467 $695,000
Q3 2021 Nov 12, 2021	BUY	$68.67 - $84.02 $187,194 - $229,038	2,726 New	2,726 $187,000
Q1 2020 May 12, 2020	SELL	$63.18 - $85.97 $694 - $945	-11 Closed	0 $0
Q4 2019 Feb 11, 2020	BUY	$73.04 - $95.72 $803 - $1,052	11 New	11 $1,000
Q4 2018 Feb 13, 2019	SELL	$58.5 - $69.94 $71,838 - $85,886	-1,228 Closed	0 $0
Q3 2018 Nov 13, 2018	SELL	$61.75 - $74.23 $741 - $890	-12 Reduced 0.97%	1,228 $85,000
Q2 2018 Aug 01, 2018	SELL	$60.85 - $83.98 $10,040 - $13,856	-165 Reduced 11.74%	1,240 $83,000
Q1 2018 May 16, 2018	BUY	$83.06 - $100.98 $80,402 - $97,748	968 Added 221.51%	1,405 $117,000
Q4 2017 Feb 13, 2018	BUY	$93.56 - $116.6 $3,368 - $4,197	36 Added 8.98%	437 $41,000
Q3 2017 Nov 08, 2017	BUY	$109.15 - $138.27 $3,711 - $4,701	34 Added 9.26%	401 $47,000
Q2 2017 Aug 15, 2017	SELL	N/A	-32 Reduced 8.02%	367 $46,000
Q1 2017 Sep 15, 2017	BUY	N/A	4 Added 1.01%	399 $53,000
Q4 2016 Sep 15, 2017	SELL	N/A	-3 Reduced 0.75%	395 $40,000
Q3 2016 Sep 15, 2017	BUY	N/A	28 Added 7.57%	398 $38,000
Q2 2016 Sep 15, 2017	SELL	N/A	-56 Reduced 13.15%	370 $30,000
Q1 2016 Sep 15, 2017	BUY	N/A	8 Added 1.91%	426 $31,000
Q4 2015 Sep 15, 2017	BUY	N/A	418	418 $45,000

Others Institutions Holding INCY

# of Institutions

643

Shares Held

186M

Call Options Held

714K

Put Options Held

557K

View Full List

About INCYTE CORP

Ticker INCY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 222,431,008
Market Cap $15.6B
Description
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as ...

More about INCY

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Assetmark, Inc, based on Form 13F filings with the SEC.

News

Stay updated on Assetmark, Inc with notifications on news.

Account